Japan Approval Another Boost For Tagrisso in 1L NSCLC

Aug 21 2018

• By Ian Haydock

Listen to this article

Following a priority review, Japan has approved AstraZeneca’s Tagrisso for the first-line treatment of inoperable or recurrent EGFR mutation-positive NSCLC, further strengthening the drug’s position in this setting.

Digital illustration of Cancer cell in colour background — TAGRISSO FOR 1L NSCLC AMONG LATEST JAPAN APPROVALS • Source: Shutterstock

A new approval from Japan’s Ministry of Health, Labour and Welfare moves AstraZeneca PLC’s Tagrisso (osimertinib) into the first-line setting in this potentially large market for the treatment of inoperable or recurrent EGFR mutation-positive non-small cell lung cancer (NSCLC), adding to the epidermal growth factor receptor tyrosine kinase inhibitor’s class lead in this indication.

As elsewhere, the approval was based on results from the global Phase III FLAURA trial, which included Japanese patients, and...

More from Japan

Progress Or Hype? A Decade Of Cell Therapy In Japan
Aug 26 2024
• By Lisa Takagi
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts
Aug 08 2024
• By Lisa Takagi
Several major Japanese firms, including Takeda, are planning layoffs at home and elsewhere as they make efforts to streamline their business and costs and cope with R&D and commercial challenges.
Japan Results Roundup: Strong Mainstays, Currency Windfall Help Top Line
Aug 06 2024
• By Lisa Takagi
Results from the top Japanese pharma firms in the fiscal first quarter were marked mainly by strong global performances for mainstay products and significant currency effects due to the continued weakness of the yen, although forex concerns are rising. Eisai's Alzheimer's drug Leqembi also gained momentum, particularly in the US.
Win Some, Lose Some: Amid Otsuka-Jnana Deal, Delaware Court Favors Lupin For gJynarque
Aug 05 2024
• By Vibha Ravi
Otsuka Pharma’s acquisition of Jnana seems like a win for its pipeline, but the Japanese major faced a setback in a Delaware District Court where the judge’s opinion put challenger Lupin closer to a generic to its Jynarque (tolvaptan)

More from Focus On Asia

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2
Oct 14 2025
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Mar 10 2025
• By Dexter Jie Yan
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.